98%
921
2 minutes
20
Objective: Despite the historical neurological use of Withania somnifera, limited evidence supports its efficacy for conditions like anxiety and insomnia. Given its known anti-stress properties, this review evaluated its safety and efficacy for anxiety and insomnia.
Methods: We searched Medline, Cochrane Library, and Google Scholar until August 2023 for randomized controlled trials (RCTs) comparing W. somnifera to placebo in patients with anxiety and/or insomnia. Outcome measures included changes in anxiety levels via the Hamilton Anxiety Scale (HAM-A), Sleep Onset Latency (SOL), Total Sleep Time (TST), Wake After Sleep Onset (WASO), Total Time in Bed (TIB), Sleep Efficiency (SE), and Pittsburgh Sleep Quality Index (PSQI) score. We utilized a random-effect model for pooling Mean Differences (MD) with a 95% Confidence Interval (CI). Heterogeneity was assessed through sensitivity and subgroup analysis, and the quality of RCTs was evaluated using the Cochrane revised risk of bias tool.
Results: Pooled results from five RCTs (n = 254) demonstrated that W. somnifera significantly reduced HAM-A scores (MD = -5.96; [95% CI -10.34, -1.59]; P = 0.008; I = 98%), as well as sleep parameters such as SOL, TST, PSQI, and SE, but not WASO and TIB.
Conclusion: While W. somnifera extracts yielded promising results, further research with larger sample sizes is needed to confirm its effects on anxiety and insomnia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/hup.2911 | DOI Listing |
Front Cardiovasc Med
August 2025
Department of Medicine, Hualien Armed Forces General Hospital, Hualien City, Taiwan.
Background: The association observed between mental stress and metabolic syndrome (MetS) has varied across studies and may be confounded by physical activity (PA) and fitness status.
Method: This study included a military cohort of 2,854 participants in Taiwan who were not taking any medications and were free of baseline MetS. The Brief Symptoms Rating Scale (BSRS-5) includes five domains-depression, anxiety, hostility, insomnia, and interpersonal sensitivity-measured on a five-point Likert-type scale ranging from 0 to 4, with a maximum score of 20.
Sleep Adv
July 2025
Department of Pediatrics, Division of Child Neurology, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, United States.
Study Objectives: Conduct a multidimensional analysis of sleep perception, objective sleep, and neuropsychiatric wellbeing in individuals with subacute concussion compared to controls.
Methods: Thirty-one recently concussed individuals completed the Pittsburgh Sleep Quality Index, Insomnia Severity Index, and Patient-Report Outcomes Measurement Information System measures of depression, anxiety, stress, and cognitive function. Concussion symptom severity scores (Sports Concussion Assessment Tool) were obtained from participants' health records.
Neuropsychopharmacol Rep
September 2025
Department of Anesthesiology and Pain Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
Background: Although opioid analgesics may influence sleep in patients with chronic pain, the association between strong opioid use and sleep characteristics remains unclear. This study aimed to explore differences in sleep status among chronic pain patients with varying levels of opioid use.
Methods: A total of 29 patients with chronic non-cancer pain who had been under treatment for more than 6 months were included.
J Assoc Nurses AIDS Care
September 2025
Seonmi Yeom, PhD, RN, is a Research Professor, College of Nursing and Research Institute of Nursing Science, Jeonbuk National University, Jeonju-si, Republic of Korea.
As the number of older people living with HIV (PLWH) continues to grow, many experience a high symptom burden that negatively affects quality of life. Identifying symptom subgroups can help inform targeted interventions. Our study explored symptom patterns among older PLWH and their associations with self-rated health.
View Article and Find Full Text PDFFront Neurol
August 2025
School of Graduate, Heilongjiang University of Chinese Medicine, Harbin, China.
Objective: Insomnia is a prevalent symptom among perimenopausal women, mainly attributed to estrogen-progesterone imbalance and neuropsychiatric factors, significantly impacting their quality of life. This article seeks to systematically evaluate the efficacy of integrated acupuncture-pharmacotherapy (AP) in treating perimenopausal insomnia (PMI), offering new insights for the management of insomnia in women.
Methods: Searches were conducted in 8 databases: PubMed, Web of Science (WOS), Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), China Biology Medicine Disc (CBM), Wanfang Academic Journal Full-text Database (Wanfang), and Chongqing VIP Database (CQVIP).